SETD2 (SET domain-containing 2, a histone lysine methyltransferase) integrates EZH2 (enhancer of zeste homolog 2) and the AMPK signaling pathway to restrict prostate cancer metastasis by linking metabolism with epigenetic modifications (Yuan et al., 2020). Here, SETD2 is linked to prostate carcinoma.